JNJ
Johnson & Johnson
$253.85
-3.92 (-1.52%)
At close · Jul 14
Market Cap
$611.07B
Shares
2,407,216,971
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$94.19B
+6%
FY2026
Net Income
$26.8B
+90.6%
FY2026
Gross Margin
67.88%
-1.2pp
FY2026
Diluted EPS
$11.03
+90.5%
FY2026
Operating Cash Flow
$24.53B
+1.1%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $96.36B | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | — | — | — | — | — | — | — | — | — | |
| $31.01B | $30.26B | $27.47B | $26.55B | $24.6B | $23.4B | $28.43B | $27.56B | $27.09B | $25.44B | $21.79B | $21.54B | $22.75B | $22.34B | $21.66B | $20.36B | $18.79B | $18.45B | $18.51B | $17.75B | |
| $65.36B | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.5B | $54.49B | $51.01B | $50.1B | $48.54B | $51.59B | $48.97B | $45.57B | $44.67B | $42.8B | $43.45B | $45.24B | $43.34B | |
| — | 67.88% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.72% | 69.69% | — | — | — | — | — | — | — | — | — | |
| $411M | $109M | $1.84B | $483M | $0 | $0 | $12.16B | $11.36B | $10.78B | $10.59B | $9.14B | $9.05B | $8.49B | $8.18B | $7.67B | $7.55B | $6.84B | $6.99B | $7.58B | $7.68B | |
| $24.6B | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B | $22.08B | $22.18B | $22.54B | $21.52B | $20.07B | $21.2B | $21.95B | $21.83B | $20.87B | $20.97B | $19.42B | $19.8B | $21.49B | $20.45B | |
| $4.7B | $4.6B | $4.5B | $4.5B | $3.9B | $4.2B | $4.7B | $4.5B | $4.4B | $3B | $1.2B | $1.2B | $1.4B | $1.4B | $1.15B | $852M | $748M | $0 | $0 | $678M | |
| — | $7.5B | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B | $5.64B | $3.75B | $3.75B | $3.9B | $4.1B | $3.67B | $3.16B | $2.94B | $2.77B | $2.83B | $2.78B | |
| $243M | $228M | $234M | $489M | $275M | $209M | $247M | $266M | $251M | $309M | $491M | $509M | $0 | $0 | $0 | $569M | $0 | $1.07B | $0 | $745M | |
| $21.77B | — | — | — | — | — | — | — | — | — | — | — | $21.59B | $16.41B | $14.96B | $13.77B | $17.7B | $16.58B | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $25.49B | $20.52B | $18.62B | $16.92B | $20.64B | $19.36B | — | — | |
| $1.04B | $971M | $755M | $772M | $276M | $183M | $201M | $318M | $1.01B | $934M | $726M | $552M | $533M | $482M | $532M | $571M | $455M | $451M | $435M | $296M | |
| $953M | $1.06B | $1.33B | $1.26B | $490M | $53M | $111M | $357M | $611M | $385M | $368M | $128M | $67M | $74M | $64M | $91M | $107M | $90M | $361M | $452M | |
| -$406M | $7.21B | -$4.69B | -$6.63B | -$810M | -$526M | -$2.9B | -$2.53B | -$1.41B | $42M | -$210M | $2.06B | $70M | -$2.5B | -$1.63B | -$2.74B | $768M | $526M | $1.02B | -$534M | |
| $24.94B | $32.58B | $16.69B | $15.06B | $19.36B | $19.18B | $16.5B | $17.33B | $18B | $17.67B | $19.8B | $19.2B | $20.56B | $15.47B | $13.78B | $12.36B | $16.95B | $15.76B | $16.93B | $13.28B | |
| $3.9B | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B | $2.7B | $16.37B | $3.26B | $3.79B | $4.24B | $1.64B | $3.26B | $2.69B | $3.61B | $3.49B | $3.98B | $2.71B | |
| $21.04B | $26.8B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.3B | $1.3B | $16.54B | $15.41B | $16.32B | $13.83B | $10.85B | $9.67B | $13.33B | $12.27B | $12.95B | $10.58B | |
| — | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.7% | 23.01% | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$339M | $0 | $0 | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $8.46B | $16.78B | $10.68B | $7.57B | $12.86B | — | — | — | |
| USD/shares | — | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 | $4.92 | $3.94 | $3.54 | $4.85 | $4.45 | $4.62 | $3.67 |
| USD/shares | — | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 |
| shares | — | 2.41B | 2.41B | 2.53B | 2.63B | 2.63B | 2.63B | 2.65B | 2.68B | 2.69B | 2.74B | 2.77B | 2.82B | 2.81B | 2.75B | 2.74B | 2.75B | 2.76B | 2.8B | 2.88B |
| shares | — | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B | 2.81B | 2.86B | 2.88B | 2.81B | 2.78B | 2.79B | 2.79B | 2.84B | 2.91B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2026: $102.68B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - General median 3.19×
EV/EBIT
—
P/E (TTM)
29.41×
Drug Manufacturers - General median 23.08×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | 2021-01-03 | 2019-12-29 | 2018-12-30 |
|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $60,401,000,000 | $56,964,000,000 | $54,759,000,000 | $52,563,000,000 | $51,680,000,000 | — | — | — |
| MedTech | $33,792,000,000 | $31,857,000,000 | $30,400,000,000 | $27,427,000,000 | $27,060,000,000 | $22,959,000,000 | — | — |
| Consumer | — | — | — | $14,953,000,000 | — | $14,450,000,000 | $13,898,000,000 | $13,853,000,000 |
| Medical Devices | — | — | — | — | — | — | $25,963,000,000 | $26,994,000,000 |
| Pharmaceutical | — | — | — | $52,563,000,000 | — | $45,175,000,000 | $42,198,000,000 | $40,734,000,000 |
By Geography (USD)
| Component | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | 2021-01-03 | 2019-12-29 | 2018-12-30 |
|---|---|---|---|---|---|---|---|---|
| United States | $53,752,000,000 | $50,302,000,000 | $46,444,000,000 | $41,981,000,000 | $40,640,000,000 | $43,133,000,000 | $42,097,000,000 | $41,884,000,000 |
| Non Us | $40,441,000,000 | $38,519,000,000 | $38,715,000,000 | $38,009,000,000 | $38,100,000,000 | $39,451,000,000 | $39,962,000,000 | $39,697,000,000 |
| Europe | $21,535,000,000 | $20,212,000,000 | $20,410,000,000 | $20,664,000,000 | $20,595,000,000 | $18,980,000,000 | $18,466,000,000 | $18,753,000,000 |
| Asia Pacific Africa | $14,031,000,000 | $13,593,000,000 | $13,756,000,000 | $13,237,000,000 | $13,578,000,000 | $15,136,000,000 | $15,555,000,000 | $14,831,000,000 |
| Western Hemisphere Excluding US | $4,875,000,000 | $4,714,000,000 | $4,549,000,000 | $4,108,000,000 | $3,927,000,000 | $5,335,000,000 | $5,941,000,000 | $6,113,000,000 |
Key facts
CIK
200406
CUSIP
478160104
13F (30d)
680 filings
612 filers
Visit website
Investor relations